Skip to main content
Article thumbnail
Location of Repository

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

By Virginia Stauffer, Haya Ascher-Svanum, Lin Liu, Tamara Ball and Robert Conley
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2009). A: A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
  2. (2007). AI: Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.
  3. (2004). American Psychiatric Association; Steering Committee on Practice Guidelines: Practice guideline for the treatment of patients with schizophrenia, second edition.
  4. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
  5. (1976). Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised.
  6. (2004). Comparison of olanzapine to other atyptical antipsychotics in preventing relapse in patients with schizophrenia [abstract].
  7. (2006). double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
  8. (2005). DR: Remission in schizophrenia: proposed criteria and rationale for consensus.
  9. (1962). DR: The Brief Psychiatric Rating Scale. Psychol Rep
  10. (2005). Dunayevich E: A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res
  11. (2006). Dursun SM: Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy.
  12. (2005). Etschel E, Engel RR: What does the PANSS mean? Schizophr Res
  13. (2003). Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry
  14. (2006). Improving patient outcomes in schizophrenia: achieving remission.
  15. (2004). Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
  16. (2007). JM: All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.
  17. (2005). JM: Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
  18. (2005). Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med
  19. (2006). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.
  20. (2008). Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. Clinical Schizophrenia & Related Psychoses
  21. Pre-publication history The pre-publication history for this paper can be accessed here: pub
  22. (2006). Siris SG: A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
  23. (2003). Tarin-Godoy B: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia:
  24. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
  25. (2008). The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
  26. (2006). Time course for antipsychotic treatment response in first-episode schizophrenia.
  27. (1997). Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
  28. (2007). Wagenpfeil S: Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology
  29. (2009). WH: A Double-Blind, Randomized,
  30. Zyprexa [package insert].

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.